Brief: Entera Bio Reports Q1 Revenue Of $157,000
20/05/2021 13:29
May 20 (Reuters) - Entera Bio Ltd 5DT.F :
* ENTERA BIO REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS
AND
PROVIDES CLINICAL UPDATES
* Q1 REVENUE $157,000
* PHASE 2 EB613 CLINICAL TRIAL IN OSTEOPOROSIS ACHIEVES
3-MONTH
PRIMARY ENDPOINT; FINAL DATA INCLUDING BMD EXPECTED Q2 2021
* EXPECTED CASH RUNWAY INTO Q2 OF 2022
* Q1 LOSS PER SHARE $0.43
Source text for Eikon: ID:nGNX25rvCb
Further company coverage: 5DT.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement